Assembly Biosciences holders approve 1.2 million share increase to 2018 stock plan
At its June 4, 2026 annual meeting, Assembly Biosciences stockholders elected nine directors, approved a non-binding advisory vote on executive pay, and ratified Ernst & Young LLP as auditor for 2026. They also approved Amendment No. 3, which raises the shares reserved under the 2018 Stock Incentive Plan from 1,478,333 to 2,678,333, and an amendment that raises the shares reserved under the Employee Stock Purchase Plan from 225,000 to 515,000.
Key points
- Amendment No. 3 adds 1,200,000 shares to the 2018 Stock Incentive Plan, bringing the reserve to 2,678,333 shares.
- The ESPP reserve rises from 225,000 to 515,000 shares under ESPP Amendment No. 2.
- Nine directors were elected, each receiving at least 11,274,020 votes for, with the ratification of Ernst & Young LLP receiving 12,382,746 votes for.
- Votes against the executive pay advisory proposal totaled 5,401, against 11,293,061 votes for.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.